

FOI 2704

29<sup>th</sup> October 2024

**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

---

**A. Please provide the number of migraine patients treated in the last 4 months with:**

Medication	Total number of patients treated
<b>Atogepant (Aquipta)</b>	0
<b>Erenumab (Aimovig)</b>	0
<b>Eptinezumab (Vyepiti)</b>	2
<b>Fremanezumab (Ajovy)</b>	7
<b>Galcanezumab (Emgality)</b>	8
<b>Rimegepant (Vydura)</b>	0
All of the above are a mixture of specialist and non-specialist	
<b>Botulinum Toxin (i.e., Botox, Dysport, Xeomin)</b>	Please see attachment

**B. How many patients have you treated in the last 4 months for acute migraine with:**

Medication	Total number of patients treated
<b>Rimegepant (Vydura)</b>	0

**C. Are you required to complete Blueteq for the following product classes:**

- **Botulinum Toxin (Botox, Dysport, Xeomin)**
- **Monoclonal antibodies (e.g. fremanezumab, erenumab, galcanezumab, eptinezumab)**
- **Gepants (e.g. rimegepant, atogepant)**

**Response:**

The Southern Trust are not required to do Blueteq for any medications.

**Email:** [FOI.team@southerntrust.hscni.net](mailto:FOI.team@southerntrust.hscni.net)